Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven stage IIB, III, or IV invasive ovarian epithelial, fallopian tube, or peritoneal cancer~* No symptomatic brain metastasis~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* WHO/ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 3,000/mm\^3~* Neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2 times upper limit of normal~Renal:~* Glomerular filtration rate at least 50 mL/min~Cardiovascular:~* No ventricular arrhythmia (LOWN class II or worse)~* No myocardial infarction within the past year~* No severe or uncontrolled hypertension~* No history of congestive heart disease (no New York Heart Association class III or IV heart disease) even if medically controlled~* LVEF at least 50%~Other:~* No other primary malignancies except carcinoma in situ of the cervix or basal cell skin cancer~* No worse than grade I preexisting motor or sensory neurologic pathology or symptoms~* No active infection or other serious underlying medical condition that would prevent compliance~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~* No other concurrent antineoplastic agents~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy~Surgery:~* Not specified

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).